Adelaide, South Australia wants to let the secret out, and be known as hub for medical devices, pharmaceuticals, biotechnology, and digital health. It boasts world-class research institutions, such as the University of Adelaide and SAHMRI, fostering innovation and collaboration. The city’s supportive government policies provide incentives, grants, and streamlined regulations for businesses. Adelaide’s skilled workforce, renowned for its expertise in health sciences, offers a talent pool to drive industry growth. Additionally, the city’s strategic location, advanced infrastructure, and strong healthcare ecosystem make it an ideal base for development, manufacturing, and market access, attracting companies in these sectors.
Australian Health Journal spoke to Jo Close, heading the Adelaide arm of MTPConnect about the opportunity its building through its role as the industry growth centre, to help increase commercialisation and collaboration across the sector, optimise the regulatory environment, improving workforce skills and access to markets globally.
One of the companies showing world leading MedTech capabilities arising from Adelaide is Additive Surgical, the first company in Australia to manufacture 3D Printed Titanium novel spinal implant technologies. Its mission is to manufacture the highest quality medical technology in Australia that positively impact the lives of people globally.
Australian Health Journal met with Co-founder and CEO Gibran Maher.
Maher states, “Additive Surgical is committed to supporting Australian innovation and works closely with the Australian clinicians, hospitals, research institutions and universities to innovate and manufacture locally.”
Maher points out the ability to compete is made possible through supportive collaboration with government, research and other enterprises seeking to learn from each other. But to truely compete in international markets, Australia’s needs to further strengthen its sovereign capability.
Currently Australia imports more than 80% of its medical devices. Large multinational companies have very strong market share in Australia and the profits from these companies are largely returned to their international shareholders.
Additive Surgical is committed to manufacturing in Australia, developing intellectual property in Australia and supporting Australian innovation and commercialisation.
You Might also like
-
Building capacity with job-ready clinical trial interns
The Victorian Comprehensive Cancer Centre Alliance, or VCCC Alliance for short, is a Victorian partnership of 10 research, academic and clinical institutions looking at improving cancer outcomes for patients.
The VCCC Alliance SKILLED clinical trial internships program is a pathway for scientists to build role-specific clinical trial knowledge, experience and in a clinical trials unit through theoretical and on-the-job training. The internship program is a 40 week intensive program to get science student interns job ready for clinical trial assistant and study coordinator internship roles.
-
Redefining diversity in clinical trials
Ensuring inclusion, diversity, equity and patient input in the development of novel drugs and medical devices has become well accepted in health care. However appropriate implementation of these elements has been a challenge for many. Only by implementing these conscious inputs can patient outcomes be improved and health disparities in marginalised groups be addressed.
Australian Health Journal spoke to Gillian Mason, Consumer and Community Involvement Lead at Hunter Medical Research Institute in Newcastle, NSW on this topic discussed at the recent ARCS Conference in Sydney.
-
Medicinal cannabis in Australia Update
According to the Australian Journal of General Practice, published by the Royal Australian College of General Practitioners, more than 130,000 medicinal cannabis approvals have been issued in Australia to date, mostly by general practitioners, with approximately 65% of these to treat chronic non-cancer pain. Despite robust supportive data from animal models, current clinical trial evidence for THC and CBD efficacy in chronic pain is incomplete. In their prescribing decisions, doctors must balance patient demand and curiosity with caution regarding potential risks and limited efficacy.
Australian Health Journal met with 3 speakers at the recent ARCS22 Conference providing an update on medicinal cannabis. The discussion with the speakers now centres on affordability and access.